ChemoCentryx: 3Q Earnings Snapshot

Associated Press |

MOUNTAIN VIEW, Calif. (AP) _ ChemoCentryx Inc. (CCXI) on Thursday reported a loss of $10.9 million in its third quarter.

The Mountain View, California-based company said it had a loss of 22 cents per share.

The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 25 cents per share.

The biopharmaceutical company posted revenue of $9 million in the period, which fell short of Street forecasts. Three analysts surveyed by Zacks expected $11.6 million.

ChemoCentryx shares have increased 97 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $11.70, a climb of 51 percent in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CCXI at https://www.zacks.com/ap/CCXI

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.